Pfizer Inc. $PFE Shares Sold by Korea Investment CORP

Korea Investment CORP lowered its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 1.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,614,654 shares of the biopharmaceutical company's stock after selling 38,435 shares during the period. Korea Investment CORP's holdings in Pfizer were worth $62,961,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Vermillion Wealth Management Inc. grew its holdings in shares of Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company's stock worth $66,000 after acquiring an additional 382 shares during the last quarter. Eagle Capital Management LLC boosted its position in shares of Pfizer by 0.3% in the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company's stock valued at $3,554,000 after purchasing an additional 390 shares during the period. Delta Financial Advisors LLC increased its stake in Pfizer by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company's stock worth $709,000 after purchasing an additional 398 shares in the last quarter. Pines Wealth Management LLC increased its stake in Pfizer by 4.4% in the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company's stock worth $235,000 after purchasing an additional 400 shares in the last quarter. Finally, Mount Vernon Associates Inc. MD raised its holdings in Pfizer by 1.0% during the 1st quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company's stock worth $1,177,000 after buying an additional 400 shares during the period. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on PFE shares. Guggenheim decreased their target price on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a report on Friday, August 7th. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. BMO Capital Markets decreased their price objective on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, July 13th. HSBC downgraded shares of Pfizer from a "buy" rating to a "hold" rating and cut their target price for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Finally, UBS Group restated a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $28.28.

Pfizer Price Performance

Shares of PFE opened at $28.00 on Monday. The business's 50-day moving average is $25.30 and its 200-day moving average is $26.25. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The company has a market capitalization of $159.59 billion, a price-to-earnings ratio of 36.84 and a beta of 0.34. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the company posted $0.78 earnings per share. The firm's quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer's payout ratio is currently 226.32%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source